Henagliflozin Reducing Infarct Size After Priamry PCI in Patients With ST Segment Elevation Myocardial Infarction

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 248 participants.

Also called NCT06187727

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 248 participants (enrolled count) (from the registry)
Sponsor
Qian geng (from the registry)
Registry
  • NCT NCT06187727
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06187727. Randomized; double masking; primary purpose treatment. Start 2023-07-01 (actual); primary completion 2025-01-01 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Henagliflozin Reducing Infarct Size After Priamry PCI in Patients With ST Segment Elevation Myocardial Infarction
Acronym
Health
Condition
Heart Failure
Intervention (Drug)
Henagliflozin
Lead sponsor
Qian geng (class: other)

Record details

Record id
cardio:ct-nct06187727
Content hash
d8d6f223a79d0ac51f46fd7f87b859d7e888a81a9b393ba97b86c10ab0757af8